Marc Schwabish, Ph.D., heads US Pharma Business Development and Licensing at Bayer. He works across Bayer’s therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships. Prior to Bayer, Dr. Schwabish had both Business Development and Alliance Management responsibilities at Eisai. His deal experience at Eisai covered a range of diseases and stages of assets — from early research technologies through commercialized therapeutics. Dr. Schwabish previously worked in Healthcare Investment Banking (Leverage Finance and M&A), Pharma Strategy Consulting, and other Pharma/Biotech companies (R&D and Product Management). He holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.